Emilie Petit-Jean, Philippe Schultz, Mickaël Burgy, Martin Demarchi, Véronique Frasie, Pierre Coliat, Delphine Exinger, Guy Bronner, Alain C. Jung, Danielle Prebay, Henri Flesch, Sébastien Guihard, Olivier Regnier-Gavier, Alicia Thiery, Thierry Petit, Christian Borel, Hélène Carinato, Florian Sirlin, and Delphine Antoni
// Christian Borel 1, 7 , Olivier Regnier-Gavier 2 , Helene Carinato 1 , Sebastien Guihard 3, 7 , Delphine Antoni 3, 9 , Martin Demarchi 1 , Florian Sirlin 4 , Delphine Exinger 2 , Emilie Petit-Jean 2 , Alicia Thiery 5 , Guy Bronner 6 , Philippe Schultz 6 , 8 , Henri Flesch 6 , Veronique Frasie 4 , Danielle Prebay 2 , Thierry Petit 1 , Alain C. Jung 7, 10 , Mickael Burgy 1 and Pierre Coliat 2, 7, 10 1 Medical Oncology Department, Centre Paul Strauss, Strasbourg, France 2 Pharmacy Department, Centre Paul Strauss, Strasbourg, France 3 Radiotherapy Department, Centre Paul Strauss, Strasbourg, France 4 Supportive Care Department, Centre Paul Strauss, Strasbourg, France 5 Biostatistics Department, Centre Paul Strauss, Strasbourg, France 6 ENT Specialist, Strasbourg, France 7 Universite de Strasbourg, Inserm IRFAC UMR_S1113, group « STREINTH », Strasbourg, France 8 Department of Otolaryngology Head and Neck Surgery, Hopitaux Universitaires de Strasbourg, Strasbourg, France 9 Radiobiology Laboratory, Centre Paul Strauss, Universite de Strasbourg, Strasbourg, France 10 Tumor biology Laboratory, Centre Paul Strauss, Universite de Strasbourg, Strasbourg, France Correspondence to: Pierre Coliat, email: pcoliat@strasbourg.unicancer.fr Keywords: HNSCC; EXTREME; re-challenge; platinum free Interval Received: November 27, 2018 Accepted: December 13, 2018 Published: December 25, 2018 ABSTRACT Background: The EXTREME protocol is the standard of care for recurrent or metastatic head and neck squamous-cell carcinoma (R/M HNSCC) in first line. Beyond the first-line except immunotherapy, poor efficacy was reported by second-line chemotherapy. Re-challenge strategies based on a repetition of the first line with platinum and cetuximab regimens might have been an option to consider. Methods: We performed a retrospective study in order to assess the efficacy of the cetuximab plus platinum doublet-based chemotherapy regimen in patients with R/M HNSCC progressing after at least 3 months of cetuximab maintenance (EXTREME protocol). We complete a retrospective review of all medical records from R/M HNSCC patients treated after 16 weeks with the EXTREME regimen and treated with a re-challenge strategy between January 2010 and December 2014 in our institution (Centre Paul Strauss, Strasbourg, France). Results: 33 patients were identified. The re-challenged strategy provided an ORR in 33.3% of cases and a DCR of 69.6% of cases. The median OS and PFS observed from the second line were 11.2 months and 6.5 months for the subset re-challenged by EXTREME or PCC regimens respectively. The response rate between patients with a platin free interval within 3 and 6 months and greater than 6 months were equal. Drugs dose intensity were better with the PCC protocol than the EXTREME regimen used as a rechallenge. Conclusions: This study suggest re-challenging strategy by these regimens could be considered beyond the first line as an option when the platin free interval is greater than 3 months.